Amgen

The decade's top 10 patent losses, worth a whopping $915B in lifetime sales
The decade's top 10 patent losses, worth a whopping $915B in lifetime sales
Fierce Pharma
patents
AbbVie
Humira
Pfizer
Lipitor
Norvasc
GSK
Advair
Sanofi
Lantus
JNJ
Remicade
AstraZeneca
Crestor
Nexium
Amgen
Neulasta
Novartis
Diovan
Flag link:
Amgen rolls new Prolia osteoporosis ads, just weeks after next-gen Evenity hits a snag
Amgen rolls new Prolia osteoporosis ads, just weeks after next-gen Evenity hits a snag
Fierce Pharma
Amgen
Prolia
osteoporosis
drug ads
Flag link:
What Kyprolis Could Do for Amgen’s Revenue Growth
What Kyprolis Could Do for Amgen’s Revenue Growth
Market Realist
Kyprolis
Amgen
Multiple Myeloma
Flag link:
Why Has 2017 Been a Horrible Year So Far for Biotech Acquisitions?
Why Has 2017 Been a Horrible Year So Far for Biotech Acquisitions?
Motley Fool
biotech
M&A
JNJ
Actelion
Takeda
Ariad Pharmaceuticals
Gilead Sciences
Pfizer
Amgen
Flag link:
Amgen falls short in Epogen patent appeal but Pfizer stumble delays competition
Amgen falls short in Epogen patent appeal but Pfizer stumble delays competition
Fierce Pharma
Amgen
Epogen
patents
Pfizer
anemia
biosimilars
Flag link:
Amgen Remains A Standout Among Biotechs
Amgen Remains A Standout Among Biotechs
Forbes
Amgen
Repatha
biotech
Flag link:
Cytokinetics inches forward with heart failure program
Cytokinetics inches forward with heart failure program
BioPharma Dive
Cytokinetics
Omecamtiv Mecarbil
Amgen
heart failure
Japan
Flag link:
As Roche wades biosimilar waters, more competitors circle Herceptin
As Roche wades biosimilar waters, more competitors circle Herceptin
BioPharma Dive
Roche
Herceptin
biosimilars
Amgen
Allergan
ABP 980
Celltrion
CT-P6
Flag link:
FDA advances two more Herceptin biosims—this time from Amgen and Teva—as Roche braces for impact
FDA advances two more Herceptin biosims—this time from Amgen and Teva—as Roche braces for impact
Fierce Pharma
FDA
Herceptin
biosimilars
Roche
Amgen
Teva Pharmaceutical
Allergan
Celltrion
Flag link:
With $39B in cash and biosim threats looming, could Amgen use a deal? Executives say not yet
With $39B in cash and biosim threats looming, could Amgen use a deal? Executives say not yet
Fierce Pharma
Amgen
biosimilars
M&A
Flag link:
Amgen second-quarter profit tops Street view, shares fall
Amgen second-quarter profit tops Street view, shares fall
Reuters
Amgen
earnings
Flag link:
Amgen And Novartis: First Mover Advantage Is A Must
Amgen And Novartis: First Mover Advantage Is A Must
Seeking Alpha
Amgen
Novartis
migraines
erenumab
CGRP blockers
Flag link:
Big Pharma Q2 Earnings Releases on Jul 25: LLY, BIIB, AMGN
Big Pharma Q2 Earnings Releases on Jul 25: LLY, BIIB, AMGN
Yahoo/Zacks.com
earnings
Eli Lilly
Biogen
Amgen
Flag link:
An Endocrinologist Explains Her View Of Tymlos And The Osteoporosis Landscape
An Endocrinologist Explains Her View Of Tymlos And The Osteoporosis Landscape
Seeking Alpha
Amgen
Radius Health
osteoporosis
Tymlos
romosozumab
Flag link:
Drugmakers face challenges marketing new heart drugs
Drugmakers face challenges marketing new heart drugs
Medical Marketing and Media
drug marketing
Amgen
Repatha
Novartis
Entresto
Ilaris
canakinumab
Merck
Anacetrapib
Flag link:
Amgen and Novartis ID the finish line in a wicked scramble for first CGRP migraine drug OK
Amgen and Novartis ID the finish line in a wicked scramble for first CGRP migraine drug OK
Endpoints
Amgen
Novartis
migraines
CGRPs
Aimovig
Flag link:
FDA rejects Amgen’s osteoporosis drug romo as rival Radius surprises with a new CEO
FDA rejects Amgen’s osteoporosis drug romo as rival Radius surprises with a new CEO
Endpoints
FDA
Amgen
osteoporosis
romosozumab
UCB Pharma
Radius Health
Tymlos
Flag link:
Novartis stocks drug cabinet with "Big-3" arthritis blockbusters
Novartis stocks drug cabinet with "Big-3" arthritis blockbusters
Yahoo/Reuters
Novartis
rheumatoid arthritis
generics
Sandoz
Amgen
Enbrel
JNJ
Remicade
AbbVie
Humira
Flag link:
Amgen's battered Kyprolis nabs a survival win, slashing death risk in Revlimid-chemo combo
Amgen's battered Kyprolis nabs a survival win, slashing death risk in Revlimid-chemo combo
Fierce Pharma
Amgen
Kyprolis
Revlimid
Celgene
Takeda
Velcade
Multiple Myeloma
Flag link:
The biosimilar pack is growing around Roche’s all-star trio, looking to rip into a $21B franchise
The biosimilar pack is growing around Roche’s all-star trio, looking to rip into a $21B franchise
Endpoints
Roche
biosimilars
Avastin
Herceptin
ABP 215
Amgen
MYL-14010
Mylan Labs
Rituxan
Flag link: